Dr. Max Lauwiner, CEO of Valsynthese, explains how small CDMOs offer agility, proximity and senior technical attention that benefits early-stage and innovative programs.
Agility and Proximity
Small partners respond quickly, adapt to changing project needs and give sponsors direct access to senior scientists.
Specialized Chemistry
Focused expertise in complex or niche chemistry can unlock programs that larger organizations deprioritize.
Supply Chain Resilience
A diversified network of specialist suppliers reduces concentration risk in the pharmaceutical supply chain.
About This White Paper
This white paper is published by Valsynthese and curated by Biotechnology Media Insights, a trusted source for pharmaceutical and biotechnology research, technical guides and industry analysis.